Human carcinoembryonic antigen,CEA ELISA Kit

Instructions
Code CSB-E04767h
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Description

The Human carcinoembryonic antigen (CEA) ELISA Kit is used to quantitatively measure the levels of CEA in human serum, plasma, or tissue homogenates. This assay employs the quantitative sandwich enzyme immunoassay technique, in which CEA in the samples or standards are sandwiched between pre-coated CEA antibody and HRP-conjugated antibody specific for CEA. Following a wash to remove any unbound reagent, the TMB substrate solution is added to the wells and color develops in proportion to the amount of CEA bound in the initial step. The color development is stopped and the intensity of the color is measured at 450 nm via a microplate reader. This kit displays many advantages, including sensitivity, specificity, precision, linearity, and recovery. The product instructions are access to more information.

CEA is normally synthesized in gastrointestinal tissue during fetal development. Babies in the womb have high CEA levels. CEA levels gradually become very low or disappear after birth. In healthy adults, serum CEA concentrations tend to be below 5 µg/mL. However, CEA levels may be increased in intestinal carcinomas and other certain types of cancers. Among the CEA family members, CEACAM5 is the only recognized tumor marker and indicator of recurrence in cancer patients, especially colorectal.

Target Name carcinoembryonic antigen-related cell adhesion molecule 5
Alternative Names Carcinoembryonic antigen ELISA Kit; Carcinoembryonic antigen-related cell adhesion molecule 5 ELISA Kit; CD66e ELISA Kit; CEA ELISA Kit; Ceacam5 ELISA Kit; CEAM5_HUMAN ELISA Kit; DKFZp781M2392 ELISA Kit; Meconium antigen 100 ELISA Kit; OTTHUMP00000199032 ELISA Kit; OTTHUMP00000199033 ELISA Kit; OTTHUMP00000199034 ELISA Kit
Abbreviation CEACAM5
Uniprot No. P06731
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates
Detection Range 5 ng/mL-120 ng/mL
Sensitivity 2 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cancer
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<10%      
Three samples of known concentration were tested twenty times on one plate to assess.  
Inter-assay Precision (Precision between assays): CV%<15%      
Three samples of known concentration were tested in twenty assays to assess.    
             
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human CEA in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)  
1:1 Average % 98  
Range % 92-106  
1:2 Average % 95  
Range % 91-99  
1:4 Average % 104  
Range % 98-114  
1:8 Average % 85  
Range % 80-89  
Recovery
The recovery of human CEA spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range  
Serum (n=5) 92 88-98  
EDTA plasma (n=4) 102 98-108  
             
             
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/ml OD1 OD2 Average Corrected  
120 1.935 2.042 1.989 1.951  
60 1.318 1.428 1.373 1.335  
30 0.844 0.864 0.854 0.816  
10 0.388 0.376 0.382 0.344  
5 0.224 0.227 0.226 0.188  
0 0.037 0.038 0.038    
Materials provided
  • A micro ELISA plate --- The 96-well plate has been pre-coated with an anti-human CEA antibody.
  • Six vials standard (1 ml/bottle)--- Dilute a bottle of the standard at dilution series, read the OD values, and then draw a standard curve.
  • One vial HRP-conjugated CEA antibody(6 ml/bottle) --- Bind to the CEA in the samples or standards and react with the substrate to make the solution chromogenic.
  • One vial Wash Buffer (20x concentrate) (15 ml/bottle) --- Wash away unbound or free substances.
  • One vial Substrate A (7ml/bottle) --- Mix with substrate B and then interact with TMB to elicit a chromogenic reaction.
  • One vial Substrate B (7ml/bottle) --- Mix with substrate A and interact with TMB to elicit a chromogenic reaction.
  • One vial Stop Solution (7ml/bottle) --- Stop the color reaction. The solution color immediately turns from blue to yellow.
  • Four Adhesive Strips (For 96 wells) --- Cover the microplate when incubation.
  • An instruction manual
Materials not provided
  • A microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
  • An incubator can provide stable incubation conditions up to 37°C±5°C.
  • Centrifuge
  • Vortex
  • Squirt bottle, manifold dispenser, or automated microplate washer
  • Absorbent paper for blotting the microtiter plate
  • 50-300ul multi-channel micropipette
  • Pipette tips
  • Single-channel micropipette with different ranges
  • 100ml and 500ml graduated cylinders
  • Deionized or distilled water
  • Timer
  • Test tubes for dilution
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

 Q&A
Q:

Could you please help me with your technical team - are the antibodies used in this ELISA kit polyclonal antibodies or monoclonal antibodies?

A:
Thanks for your inquiry.
#CSB-E04767h,Human carcinoembryonic antigen,CEA ELISA Kit
Capture antibody:mouse monoclonal antibody;Detection antibody:mouse monoclonal antibody.

Target Data

Function Cell surface glycoprotein that plays a role in cell adhesion and in intracellular signaling. Receptor for E.coli Dr adhesins.
Gene References into Functions
  1. Positive CEA mRNA in low rectal cancer is a factor that predisposes patients to a high risk for overall recurrence, especially for local recurrence. PMID: 28291565
  2. High carcinoembryonic antigen elevation is associated with recurrence in rectal cancer. PMID: 29774483
  3. CEA and CA19-9 are cancer antigens that are late markers of carcinogenesis, with significantly elevated serum concentrations in case of colon cancer with already developed metastases. Older age group of patient has significantly elevated levels of both antigens. Cancer was twice more common in men than in women. PMID: 25568506
  4. High CEA expression is associated with breast cancer metastasis. PMID: 29433529
  5. Pretreatment serum CEA levels over 30.02 ng/mL on behalf of worse characteristics and unfavourable tumor behavior, and a poor prognosis for a nearly doubled risk of mortality in gastric cancer patients. PMID: 29358864
  6. Elevation of CEA level was an independent risk factor for the poor prognosis of early gastric cancer. PMID: 29121872
  7. The elevation of serum CEA level was independent from the other tumor markers in hypohidrotic condition represented by acquired idiopathic generalized anhidrosis. PMID: 28295553
  8. Elevated CEA levels during targeted therapy may be a more sensitive predictor of explosive lung adenocarcinoma progression in patients harboring mutant EGFRs compared to traditional imaging methods. PMID: 28705152
  9. Increased CEA expression is associated with colorectal cancer. PMID: 28128739
  10. The detection of TK1 combined with that of cytokeratin-19 fragment (CYFRA21-1), CEA or NSE increased the diagnostic value of TK1 for lung squamous cell carcinoma, adenocarcinoma and small cell lung cancer, respectively. PMID: 29247745
  11. In patients with non-small-cell lung cancer treated with nivolumab, worse pretreatment performance status, and higher carcinoembryonic antigen were associated with inferior progression-free survival. PMID: 29277824
  12. To examine the relation of carcinoembryonic antigen (CEA) response with tumor response and survival in patients with (K)RAS wild-type metastatic colorectal cancer receiving first-line chemotherapy in the FIRE-3 trial comparing FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab PMID: 27234640
  13. This is the first population-based investigation of a large cohort of exclusively stage I rectal cancer patients providing compelling evidence that elevated preoperative CEA level is a strong predictor of worse overall and cancer-specific survival. PMID: 27067235
  14. Elevated levels of systemic IFNgamma and IL-6 implied that the CEACAM5-specific T cells had undergone immune activation in vivo but only in patients receiving high-intensity pre-conditioning. PMID: 28660319
  15. Combination of the two tumor markers, CEA and CYFRA21-1, is a predictive and prognostic marker of docetaxel monotherapy for previously treated NSCLC patients PMID: 28870944
  16. Patients with CEA-High stage I NSCLC have a higher risk of regional or systemic relapse and should be followed-up carefully. PMID: 28870949
  17. Postoperative CEA level >2.5 ng/ml is a predictor of distant metastasis and a negative prognostic factor for survival in rectal cancer patients who receive preoperative chemoradiotherapy and curative surgery. PMID: 27553616
  18. Data show that triple-negative breast cancer (TNBC) patients with pre-therapeutic serum high levels of both carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) had shorter overall survival (OS) and disease-free survival (DFS) rates than those in the low-level groups. PMID: 27561099
  19. Serum CEA level is not influenced by the presence of benign dominant biliary stricture or superimposed bacterial cholangitis in patients with primary sclerosing cholangitis. PMID: 27943017
  20. Preoperative-CEA was elevated (>/=5.0 ng/mL) in 73.6% of the colorectal cancer patients and remained elevated after surgery in 32.7% of the patients. Elevated postoperative-CA 19-9 (>/=50 U/mL) was observed in 9.5% of the patients. Neither elevated pre-CEA nor elevated pre-CA 19-9 was associated with relapse-free survival (RFS) but both elevated post-CEA and elevated post-CA 19-9 were associated with reduced RFS. PMID: 27664887
  21. the diagnostic sensitivity and specificity of serum reactive oxygen species modulator 1 were only 41.38% and 86.21%, respectively, with the cutoff value of 27.22 ng/mL. The sensitivity and specificity of pleural fluid carcinoembryonic antigen were 69.23% and 88.00%, respectively, at the cutoff value of 3.05 ng/mL, while serum carcinoembryonic antigen were 80.77% and 72.00% at the cutoff value of 2.60 ng/mL. PMID: 28459208
  22. Taken together, the results of our study identified CEACAM5 as a novel cell surface binding target of Middle East respiratory syndrome coronavirus that facilitates infection by augmenting the attachment of the virus to the host cell surface. PMID: 27489282
  23. Data show that carcinoembryonic antigen (CEA) modestly differentiated between mucinous and nonmucinous lesions, and amylase did not distinguish intraductal papillary mucinous neoplasms (IPMNs) from mucinous cystadenomas (MCAs). PMID: 26646270
  24. In this study, we detected the tumor marker carcinoembryonic antigen (CEA) using the QD-LFTS system, which allowed quantitative analysis in the range of 1-100ng/mL with an ideal detection limit of 0.049ng/mL. Thus, the system is suitable for detecting CEA in the clinically accepted range. We also detected 70 positive and 30 negative serum samples using the Handing system, which exhibited good specificity and sensitivity. PMID: 27825889
  25. As a proof-of-concept study, the constructed platform exhibits good specificity for CEA and the detection limit reaches as low as 8pg/mL (45 fM) with a wide linear range from 0.01 to 60ng/mL in the both cases PMID: 27886601
  26. Under the optimal conditions, the proposed immunosensor was used for the detection of CEA with wide dynamic range in the range from 5 fg/mL to 50ng/mL with a low detection limit of 2fg/mL (S/N=3). PMID: 27871047
  27. Relative CL intensity of all-in-one dual-aptasensor, operated with the competitive reaction of CEA and hemin in the presence of the dual aptamer, was exponentially decreased with the increase of CEA concentration in human serum PMID: 27875751
  28. Data indicate that serum tumor markers showed significant shorter 3-year progression-free survival (PFS) in higher levels compared to lower levels for S-CYFRA 21-1 (cytokeratin 19 fragment), S-SCCA and S-CEA. PMID: 26432331
  29. Multivariate logistic regression analysis revealed TC and DeltaCEA as independent factors in predicting TRG; TC showed a sensitivity of 62.79 %, a specificity of 91.49 %, a Youden index of 0.543, a cutoff value of 5.52, and an AUC of 0.800 compared with DeltaCEA (sensitivity 76.74 %, specificity 65.96 %, Youden index 0.427, and AUC 0.761). PMID: 26531721
  30. Data suggest that joint detection of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) and carcinoembryonic antigen (CEA) can improve the diagnostic sensitivity and specificity. PMID: 26438059
  31. High CEA level is associated with Oral Squamous Cell Carcinoma. PMID: 27165212
  32. High CEA expression is associated with metastasis and recurrence in endometrial cancer. PMID: 26779635
  33. ZKSCAN3 appears to promote colorectal tumor progression and invasion. ZKSCAN3 may facilitate hepatic metastasis of CRC associated with CEA particularly in cases with CEA-producing tumor PMID: 27127149
  34. we evaluated the clinical performance of LOCItrade mark-based tumor marker assays CEA, CA19-9, CA15-3, CA125 and AFP in patients with gastrointestinal cancer and demonstrated their high diagnostic power PMID: 28011514
  35. High carcinoembryonic Antigen expression is associated with gastric cancer. PMID: 25124614
  36. High CEA expression is associated with Squamous cell carcinoma of the skin. PMID: 27039776
  37. Preparation of Au-polydopamine functionalized carbon encapsulated FeO magnetic nanocomposites and their application for ultrasensitive detection of carcino-embryonic antigen. PMID: 26868035
  38. Elevated Carcinoembryonic Antigen Levels are associated with Colon Cancer. PMID: 26759308
  39. Baseline serum CEA levels can serve as predictive factors for the treatment of EGFR-TKI in non-small cell lung cancer patients harboring EGFR mutations. PMID: 27072247
  40. BALF and serum NSE, CEA, and CYFRA21.1 elevated in lung cancer, which had prompt value for pathology, especially significant for BALF. PMID: 27072263
  41. Significant levels of CEA, CYFRA 21-1, NSE, and TSGF were detected in the serum. The amounts found were useful for diagnosing non-small cell lung cancer (NSCLC) patients who depended on the currently limited biomarker development. PMID: 27072222
  42. We conclude that patients with high preoperative serum CEA levels should have more intensive follow-up for detection of synchronous liver metastasis. PMID: 26756614
  43. Elevated CEA expression is associated with Gastric Cancer. PMID: 26620645
  44. CEA, NSE, CA125 and pro-GRP could serve as biomarkers for SCLC, and CEA and CYFRA21-1 could serve as biomarkers for NSCLC. Pro-GRP, CA125 and CEA were related to the clinical stages of lung cancer PMID: 26560853
  45. In this phase I/II study, 14 high-risk disease-free ovarian (OC) and breast cancer (BC) patients after completion of standard therapies were vaccinated with MUC1, ErbB2 and carcinoembryonic antigen (CEA) HLA-A2+-restricted peptides and Montanide. PMID: 26892612
  46. combined pre-chemoradiotherapy CEA and post-chemoradiotherapy CEA levels enable more accurate prediction of rectal adenocarcinoma prognosis PMID: 26962798
  47. ESCC patients with lower Cyfra21-1 and CEA, higher miR-7 and severe myelosuppression were much more sensitive to CRT. PMID: 26708917
  48. Cyst fluid CEA levels have a clinically suboptimal accuracy level in differentiating pancreatic mucinous cystic neoplasms from pancreatic nonmucinous cystic neoplasms. PMID: 26077458
  49. High carcinoembryonic antigen expression is associated with Colon Adenomas. PMID: 27100181
  50. Serum CYFRA21-1 and CEA can be used as prognostic factors of NSCLC patients. Combinative detection of the two indices will be more reliable. PMID: 26333429

Show More

Hide All

Subcellular Location Cell membrane, Lipid-anchor, GPI-anchor
Protein Families Immunoglobulin superfamily, CEA family
Tissue Specificity Found in adenocarcinomas of endodermally derived digestive system epithelium and fetal colon.
Database Links

HGNC: 1817

OMIM: 114890

KEGG: hsa:1048

STRING: 9606.ENSP00000221992

UniGene: Hs.709196

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2021 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1